Toshiba receives FDA clearance for Vantage ZGV MRI system

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

At the annual meeting of the American College of Cardiology this week in Atlanta, Toshiba America Medical Systems Inc. (TAMS) announced FDA clearance for its high-performance Excelart Vantage ZGV 1.5T MRI system. The new Vantage ZGV is immediately available and offers new product sequences, enhanced image quality, and features the Mach 8 processor, increasing reconstruction to 1300 images per second for more powerful clinical applications.

The Vantage ZGV offers a gradient strength of 33 mT/m (milliTesla per meter), a slew rate of 200 mT/m/ms (milliTesla per meter per millisecond) and delivers the highest homogeneity of any magnet in the industry over the full 50 cm diameter spherical volume (DSV). Field upgrade kits to the new ZGV are available to current Vantage users.

In addition to the ZGV model, the Vantage is available in three other versions offering an ultra-short magnet at 140 cm with linear 30 mT/m gradient strength and a slew rate of 50 mT/m/ms on the AGV, the 86 mT/m/ms on the MGV and 130 mT/m/ms on the XGV.

The Vantage includes optional packages for cardiac imaging, advanced echo planar imaging (EPI), perfusion and diffusion imaging, peripheral MRA (magnetic resonance angiography), and SuperFASE (Fast Advanced Spin Echo) imaging. In addition, Toshiba has pioneered research into contrast-free MRA with its Fresh Blood Imaging (FBI) protocol and Body Diffusion.